Gastroparesis Drugs Market is forecast to grow at a CAGR of 4.4%, reaching a market size of $6,662.35 million by the year 2032

The global gastroparesis drugs market is poised for steady growth in the coming years, driven by the increasing prevalence of gastroparesis, advancements in drug development, and a growing emphasis on improving patient outcomes. Gastroparesis is a digestive disorder that slows down the emptying of the stomach, leading to a range of symptoms such as nausea, vomiting, and abdominal pain.

Market Overview:

The global gastroparesis drugs market size was valued at USD 4,529.75 million in 2023 and is anticipated to grow from USD 4,720.90 million in 2024 to USD 6,662.35 million by 2032, exhibiting a CAGR of 4.4% during the forecast period. This growth reflects the increasing demand for effective and well-tolerated medications to manage the symptoms and improve the quality of life for individuals with gastroparesis.

Some of the major players operating in the global market include:

Abbott Laboratories (US)
AbbVie Inc. (US)
Allergan Inc. (US)
Evoke Pharma (US)
Medtronic Plc (Ireland)
Neurogastrx Inc. (US)
Pfizer Inc. (US)
Rhythm Pharmaceuticals Inc. (US)
Salix Pharmaceuticals (US)
TEVA Pharmaceutical (Israel)
Vanda Pharmaceuticals Inc. (US)

Key Market Drivers:

Rising Prevalence of Gastroparesis: The increasing prevalence of gastroparesis, particularly among individuals with diabetes, is a major driver of market growth.
Advancements in Drug Development: Ongoing research and development efforts are focused on developing novel therapies for gastroparesis, including new drug candidates with improved efficacy and safety profiles.
Growing Awareness and Diagnosis: Increased awareness of gastroparesis and improved diagnostic techniques are leading to earlier diagnosis and more timely treatment initiation.
Need for Improved Treatment Options: Existing treatments for gastroparesis may have limitations, such as side effects or limited efficacy. The need for more effective and well-tolerated medications is driving the development of new therapies.

𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐥 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬:

Gastroparesis Drugs Market, Drug Class Outlook (Revenue – USD Million, 2019-2032)

Prokinetic Agents
Antiemetic Agents
Botulinum Toxin Injections

Gastroparesis Drugs Market, Disease Class Outlook (Revenue – USD Million, 2019-2032)

Diabetic Gastroparesis
Idiopathic Gastroparesis
Post-surgical Gastroparesis
Others

Gastroparesis Drugs Market, End User Outlook (Revenue – USD Million, 2019-2032)

Hospitals
Pharmacies
Clinics
E-commerce

The research study includes segmental analysis that divides the market into distinct groups or segments based on common characteristics. With market segmentation, businesses can identify specific customer groups that are more likely to be interested in specific products or services. Also, it enables these businesses to focus their marketing efforts and resources more efficiently, leading to higher conversion rates and improved return on investment. Furthermore, segmentation analysis helps companies develop personalized products or services, which can result in increased customer loyalty and improved customer satisfaction.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞:

https://www.polarismarketresearch.com/industry-analysis/gastroparesis-drugs-market

Recent Developments:

Renexxion Ireland’s Phase IIb Trial: In February 2023, Renexxion Ireland announced the initiation of a Phase IIb trial to evaluate the safety and efficacy of naronapride, a potential new treatment for gastroparesis.
Evoke Pharma’s Patent Grant: In November 2022, Evoke Pharma was granted a new US patent for methods of treating gastroparesis with metoclopramide. This patent provides intellectual property protection for the company’s existing product and may support further development of gastroparesis therapies.

Conclusion

The global gastroparesis drugs market is poised for continued growth, driven by the increasing prevalence of the condition, advancements in drug development, and the growing need for effective treatment options. Continued research and development efforts, along with the introduction of new and improved therapies, are expected to play a crucial role in improving the lives of individuals living with gastroparesis.

Table of Contents:

Global Gastroparesis Drugs Market Insights
4.1. Gastroparesis Drugs Market – End User Snapshot
4.2. Gastroparesis Drugs Market Dynamics
4.2.1. Drivers and Opportunities
4.2.1.1. Rising prevalence of diabetes and geriatric population to boost market growth
4.2.1.2. Regulatory approvals for new drugs for gastroparesis treatment to boost market growth.
4.2.2. Restraints and Challenges
4.2.2.1. Lack of novel treatment options and regulatory hurdles to restrain growth
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers (Moderate)
4.3.2. Threats of New Entrants: (Low)
4.3.3. Bargaining Power of Buyers (Moderate)
4.3.4. Threat of Substitute (Moderate)
4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Gastroparesis Drugs Market End User Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis
5. Global Gastroparesis Drugs Market, by Disease Class
5.1. Key Findings
5.2. Introduction
5.2.1. Global Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
5.3. Diabetic Gastroparesis
5.3.1. Global Gastroparesis Drugs Market, by Diabetic Gastroparesis, by Region, 2019-2032 (USD Million)
5.4. Idiopathic Gastroparesis
5.4.1. Global Gastroparesis Drugs Market, by Idiopathic Gastroparesis, by Region, 2019-2032 (USD Million)
5.5. Post-surgical Gastroparesis
5.5.1. Global Gastroparesis Drugs Market, by Post-surgical Gastroparesis, by Region, 2019-2032 (USD Million)
5.6. Others
5.6.1. Global Gastroparesis Drugs Market, by Others, by Region, 2019-2032 (USD Million)
6. Global Gastroparesis Drugs Market, by Drug Class
6.1. Key Findings
6.2. Introduction
6.2.1. Global Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
6.3. Prokinetic Agents
6.3.1. Global Gastroparesis Drugs Market, by Prokinetic Agents, by Region, 2019-2032 (USD Million)
6.4. Antiemetic Agents
6.4.1. Global Gastroparesis Drugs Market, by Antiemetic Agents, by Region, 2019-2032 (USD Million)
6.5. Botulinum Toxin Injections
6.5.1. Global Gastroparesis Drugs Market, by Botulinum Toxin Injections, by Region, 2019-2032 (USD Million)